How to Get Involved in Alström Syndrome Research

For a rare condition like Alström Syndrome, research advances when patients and families participate. Even relatively small numbers of patient contributions — to registries, natural-history studies, biobanks, and clinical trials — substantially advance the field. This article covers the ways to participate and why it matters.

Alström Syndrome affects roughly 1 in 1,000,000 people worldwide. With perhaps 1,200 known cases globally, every patient who participates in research disproportionately contributes to understanding. Registry participation:

• Builds the natural history database
• Identifies patients eligible for future trials
• Enables researchers to recognize patterns
• Informs guidelines and best practices
• Provides the data foundation for new therapies

Without patient participation, research can't advance.¹

The Alström Syndrome International registry

ASI maintains the world's largest Alström clinical database. Participation involves:

• Sharing medical records and updates over time
• Periodic surveys
• Optional research studies that may emerge
• Connection to potential clinical trials

The registry is privacy-protected. Personal information is used for research, not shared inappropriately. Enrollment is straightforward through ASI.

Natural history studies

Various academic centers conduct natural history studies — research that tracks disease progression over time. These studies typically:

• Don't involve experimental treatments
• Require periodic visits or remote check-ins
• Provide data for research without specific risks to participants
• Sometimes provide some benefit (comprehensive evaluation)

Major centers including the GBMC, Indiana University, and Birmingham (UK) have natural history components to their work.

Biobanks

Some research programs collect blood, tissue, or other biological samples for current and future research. Sample donation typically:

• Is part of a clinical visit
• Involves informed consent
• Provides material for understanding mechanisms and developing treatments

Clinical trials

For active interventional studies, patients may be eligible based on specific criteria. Trial types include:

• Observational (data only)
• Phase 1 (safety in small numbers)
• Phase 2 (efficacy testing)
• Phase 3 (larger efficacy and safety)
• Phase 4 (post-approval surveillance)

Most current Alström-specific trials are observational rather than therapeutic, but the picture is changing.

Patient advocacy and lived-experience research

Patient and family perspectives shape research priorities. Ways to contribute:

• Patient-reported outcome measures
• Surveys about quality of life
• Advisory roles for research projects
• Speaking at conferences
• Writing about your experience

Fundraising and direct support

Patient organizations fundraise for research. Donations and fundraising events directly support investigator work. Some donations go to specific projects; others to the general research mission.

Time commitment

Varies dramatically:

• Registry: minimal — periodic surveys and record sharing
• Natural history: occasional visits or remote contact
• Clinical trials: more substantial — visits, tests, perhaps treatment

Risks and benefits

Discussed during informed consent. Most observational research has minimal risk; interventional trials have specific risks.

Privacy

Modern research follows strict privacy protections. Data is typically de-identified for analysis.

Cost

Most research participation is free for participants. Some studies cover travel costs.

Rights of participants

Participants retain the right to:

• Withdraw at any time
• Decline specific procedures
• Receive their own results when applicable
• Have their privacy protected

Through patient organizations

ASI, ASUK, and Alström Angels announce research opportunities through their networks. Joining their mailing lists keeps you informed.

Through your medical team

Specialists at centers of excellence often know of relevant research. Asking directly is appropriate.

ClinicalTrials.gov

Search for "Alström" or "ALMS1" to find listed US trials. Other countries have equivalent registries.

Academic centers

The major academic Alström centers have research components. Direct contact through center websites or coordinators may identify opportunities.

The Alström research community has identified priority areas:

Therapeutic development

• Gene therapy for ALMS1
• Antisense oligonucleotides for specific variants
• Novel pharmacology for downstream complications
• Drug repurposing studies

Better understanding mechanisms

• Cellular and molecular basis of multisystem involvement
• Genotype-phenotype correlations
• Modifying factors that affect severity

Better clinical care

• Validated biomarkers for monitoring
• Improved diagnostic algorithms
• Cost-effectiveness of interventions
• Quality of life outcomes

Patient-centered research

• Lived experience of patients and families
• Mental health needs
• Effective intervention design
• Outcomes that matter to patients

For most participants, registry participation has little day-to-day impact. Natural history studies may add some appointments. Clinical trials are more involved.

Many participants describe meaning in contributing — whether to science, to future patients, or to feeling agency in a condition that often feels uncontrollable.

Your relationship with research can evolve:

• Some participants engage deeply
• Some engage minimally
• Some shift over time as their interest or capacity changes
• Some connect with research as their child gets older

There's no single right way to participate.

• Alström Syndrome Research and Clinical Trials in 2026
• Alström Syndrome Support Organizations
• The History of Alström Syndrome
• Alström Syndrome Genetics: ALMS1 Gene Explained
• Alström Syndrome Centers of Excellence

April 30, 2026.